Targeting new markets

How to reach us

M1 Kliniken AG
Grünauer Straße 5
12557 Berlin
Germany

T. +49 (0)30 347 47 44 14
E.

For medical consultation appointments contact: https://www.m1-beauty.de/termine/

Contact

Data protection*

Latest news

  • Group revenue: +9.5% to EUR 92.7 million (Q1 2024: EUR 84.7 million)
  • EBITDA: +22% to EUR 10.0 million (Q1 2024: EUR 8.2 million)
  • EBIT: +29% to EUR 8.8 million (Q1 2024: EUR 6.8 million)
  • EBIT margin: 9.5% (Q1 2024: 8.1%)
  • EBT: +23% to EUR 8.6 million (Q1 2024: EUR 7.0 million)
  • Earnings per share: EUR 0.31 (Q1 2024: EUR 0.26)

| Investor News

  • Group revenue increased by 7% to EUR 339.2 million (previous year: EUR 316.3 million)
  • EBITDA rose by 52% to EUR 32.0 million (previous year: EUR 21.0 million)
  • EBIT grew by 70% to EUR 26.8 million (previous year: EUR 15.7 million)
  • EBT increased by 60% to EUR 26.3 million (previous year: EUR 16.4 million)
  • Beauty segment revenue rose by 30% to EUR 91.7 million (previous year: EUR 70.8 million)
  • Equity ratio improved from 67% to 71%

| Investor News

  • Group revenue: increase by 7% to EUR 339.2 million (previous year: EUR 316.3 million)
  • EBITDA: increase by 52% to EUR 32.0 million (previous year: EUR 21.0 million)
  • EBIT: increase by 70% to EUR 26.8 million (previous year: EUR 15.7 million)
  • EBT: increase by 60% to EUR 26.3 million (previous year: EUR 16.4 million)
  • Earnings per share: increase of 57% to EUR 0.85 (previous year: EUR 0.54)
  • Equity ratio: increase from 67% to 71%

| Ad-hoc news

HAEMATO AG, which is majority-owned by M1 Kliniken AG, has received a so-called Conditional Binding Offer (CBO) for the acquisition of its trading segment, the wholly-owned subsidiary HAEMATO PHARM GmbH. The Executive Board and Supervisory Board of HAEMATO AG are currently carefully reviewing the offer.

A possible sale of the trade segment would pave the way for a clear strategic focus of M1 Kliniken AG on the fast-growing beauty business.

The company will provide further information in due course.